Pharma-Funded FDA Gets Drugs Out Faster, But Some Work Only ‘Marginally’ and Most Are Pricey
Since pharmaceutical companies started funding their FDA drug applications 30 years ago, the agency’s reviews have gone much faster — perhaps too fast.
Big Pharma Went All In to Kill Drug Pricing Negotiations
For more than a century, the drug industry has issued dire warnings of plunging innovation whenever regulation reared its head. In general, the threat hasn’t materialized.
Qué significa el caso de Nueva York para el fin de la polio
Para 2015, la polio se había erradicado casi por completo en todas partes excepto en Pakistán y Afganistán. Pero para 2020 se habían reportado casos en 34 países.
What the Polio Case in New York Tells Us About the End of Polio
The Rockland County case isn’t expected to cause a major outbreak, but it shows how even this rare disease can pop up in undervaccinated communities.
Boost Now or Wait? Many Wonder How Best to Ride Out Covid’s Next Wave
As the country faces a rise in new infections driven by the omicron BA.5 subvariant of the coronavirus, about 70% of people 50 and older who got a first covid-19 booster shot haven’t received the recommended second one, according to the Centers for Disease Control and Prevention. Many undervaccinated Americans have lost interest, and others aren’t sure whether to get boosted again now or wait for vaccines reformulated to target newer strains of the virus.
¿Ponerse el refuerzo ahora o esperar? Muchos se preguntan cómo navegar la próxima ola de covid
Aproximadamente el 70% de los estadounidenses de 50 años o más que recibieron una primera vacuna de refuerzo contra covid, y casi la misma cantidad de personas de 65 años o más, no han recibido un segundo, según datos de los CDC.
As Big Pharma Loses Interest in New Antibiotics, Infections Are Only Growing Stronger
Existing drugs still treat most infections. But that has discouraged investment in new drugs that will be needed when — not if —the old ones fail.
How Pfizer Won the Pandemic, Reaping Outsize Profit and Influence
The drugmaker has the best-selling vaccine to prevent covid and the most effective drug to treat it. Its success has overshadowed the government’s covid-fighting strategy.
Cómo Pfizer le ganó a la pandemia, alcanzando influencia y ganancias descomunales
Su éxito en el desarrollo de medicamentos contra covid le ha dado a la farmacéutica un peso inusual en la determinación de la política de salud de Estados Unidos. Algo que preocupa a expertos.
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
After years of failure, the Maryland company aims to attract the vaccine-hesitant with an alternative to mRNA shots. But will it find a market?